Accelerating drug development in breast cancer: New frontiers for ER inhibition

This publication has 99 references indexed in Scilit:

• Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
  Cell Reports, 2013
• Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
  The Lancet Oncology, 2013
• Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease
  Clinical Cancer Research, 2013
• The Selective Estrogen Receptor Modulator Bazedoxifene Inhibits Hormone-Independent Breast Cancer Cell Growth and Down-Regulates Estrogen Receptor α and Cyclin D1
  Molecular Pharmacology, 2011
• Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients
  Journal of Clinical Oncology, 2010
• A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
  New England Journal of Medicine, 2005
• Structural Basis for an Unexpected Mode of SERM-Mediated ER Antagonism
  Molecular Cell, 2005
• Mechanisms of tamoxifen resistance
  Endocrine-Related Cancer, 2004
• Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women
  Cancer, 2003
• Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group
  Journal of Clinical Oncology, 2003